Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study | Translational Psychiatry - Nature.com
Submitted by Anonymous (not verified) on Mon, 11/21/2022 - 08:00
